EQS-News: Evotec SE / Schlagwort(e): Personalie Evotec SE ernennt Dr. Christian Wojczewski zum Chief Executive Officer 23.04.2024 / 20:40 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Hamburg, 23. April 2024: Der Aufsichtsrat der Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) hat Dr. Christian Wojczewski mit Wirkung zum 1. Juli 2024 zum Chief Executive Officer („CEO“) von Evotec ernannt. Die Wahl erfolgte...
EQS-Ad-hoc: Evotec SE / Schlagwort(e): Personalie Evotec SE ernennt Dr. Christian Wojczewski zum Chief Executive Officer 23.04.2024 / 20:38 CET/CEST Veröffentlichung einer Insiderinformation nach Artikel 17 der Verordnung (EU) Nr. 596/2014, übermittelt durch EQS News - ein Service der EQS Group AG. Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Hamburg, Deutschland – Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480...
EQS-Ad-hoc: Evotec SE / Key word(s): Personnel Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer 23-Apr-2024 / 20:38 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:...
HAMBURG, GERMANY / ACCESSWIRE / April 23, 2024 / The Supervisory Board of Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) has appointed Dr Christian Wojczewski as the Company's new Chief Executive Officer ("CEO"), effective 01 July 2024. The election was unanimous and is the result of an extensive selection process that began in January. Dr Mario Polywka, who has led Evotec as Interim CEO since 03 January 2024, will retire from his position at the end of...
EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec and Variant Bio enter strategic partnership to discover and develop fibrosis treatments 18.04.2024 / 13:27 CET/CEST The issuer is solely responsible for the content of this announcement. COLLABORATION LEVERAGES VARIANT BIO’S CUTTING-EDGE GENOMIC DISCOVERY PLATFORM AND EVOTEC’S INTEGRATED END-TO-END R&D PLATFORM AND DISEASE AREA EXPERTISE TO ADDRESS UNMET MEDICAL NEED IN FIBROTIC INDICATIONS COMMERCIAL TERMS INCLUDE RESEARCH FUNDING AND...
EQS-News: Evotec SE / Schlagwort(e): Sonstiges Evotec und Variant Bio gehen strategische Partnerschaft zur Entdeckung und Entwicklung von Fibrose-Behandlungen ein 18.04.2024 / 13:27 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. DIE KOLLABORATION NUTZT VARIANT BIOS HOCHMODERNE GENOMIK-FORSCHUNGSPLATTFORM UND EVOTECS INTEGRIERTE END-TO-END F&E-PLATTFORM UND EXPERTISE IM KRANKHEITSBEREICH, UM UNGEDECKTEN MEDIZINISCHEN BEDARF IN FIBROTISCHEN INDIKATIONEN...
EVOTEC AND VARIANT BIO ENTER STRATEGIC PARTNERSHIP TO DISCOVER AND DEVELOP FIBROSIS TREATMENTS PR Newswire HAMBURG, Germany and SEATTLE, April 18, 2024 COLLABORATION LEVERAGES VARIANT BIO'S CUTTING-EDGE GENOMIC DISCOVERY PLATFORM AND EVOTEC'S INTEGRATED END-TO-END R&D PLATFORM AND DISEASE AREA EXPERTISE TO ADDRESS UNMET MEDICAL NEED IN FIBROTIC INDICATIONS COMMERCIAL TERMS INCLUDE RESEARCH FUNDING AND MILESTONES AND/OR ROYALTY PAYMENTS TO EVOTEC BASED ON THE OVERALL SUCCESS OF THE PROGRAM...
COLLABORATION LEVERAGES VARIANT BIO'S CUTTING-EDGE GENOMIC DISCOVERY PLATFORM AND EVOTEC'S INTEGRATED END-TO-END R&D PLATFORM AND DISEASE AREA EXPERTISE TO ADDRESS UNMET MEDICAL NEED IN FIBROTIC INDICATIONS COMMERCIAL TERMS INCLUDE RESEARCH FUNDING AND MILESTONES AND/OR ROYALTY PAYMENTS TO EVOTEC BASED ON THE OVERALL SUCCESS OF THE PROGRAMME HAMBURG, GERMANY AND SEATTLE, WA / ACCESSWIRE / April 18, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) and...
EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec SE to announce results for fiscal year 2023 on 24 April 2024 17.04.2024 / 15:00 CET/CEST The issuer is solely responsible for the content of this announcement. Hamburg, Germany, 17 April 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for 2023 on Wednesday, 24 April 2024. The Company is going to hold a conference call to discuss the results as well as provide...
EQS-News: Evotec SE / Schlagwort(e): Sonstiges Evotec SE: Bekanntgabe der Ergebnisse für das Geschäftsjahr 2023 am 24. April 2024 17.04.2024 / 15:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Hamburg, 17. April 2024: Die Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) veröffentlicht am Mittwoch, 24. April 2024, ihren Bericht über das Geschäftsjahr 2023. In einer Telefonkonferenz in englischer Sprache...
HAMBURG, GERMANY / ACCESSWIRE / April 17, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for 2023 on Wednesday, 24 April 2024. The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English. Webcast details Date: Wednesday, 24 April 2024 Time: 3.00 pm CEST (02.00 pm BST, 09.00 am EDT) To join the audio webcast and...
EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec welcomes Aurélie Dalbiez as Chief People Officer 17.04.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. Hamburg, Germany, 17 April 2024: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the appointment of Aurélie Dalbiez as the Company’s new Chief People Officer (“CPO”), effective 15 June 2024. Aurélie will be joining Evotec’s...
EQS-News: Evotec SE / Schlagwort(e): Sonstiges Evotec heißt Aurélie Dalbiez als Chief People Officer willkommen 17.04.2024 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Hamburg, 17. April 2024: Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) gab heute die Ernennung von Aurélie Dalbiez als neue Chief People Officer („CPO“) des Unternehmens mit Wirkung zum 15. Juni 2024 bekannt. Als neues...
HAMBURG, GERMANY / ACCESSWIRE / April 17, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced the appointment of Aurélie Dalbiez as the Company's new Chief People Officer ("CPO"), effective 15 June 2024. Aurélie will be joining Evotec's Management Board, bringing with her a wealth of experience and expertise in Human Resources leadership. In her role as CPO, Aurélie will oversee the development and implementation of Evotec's people...
EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec and Claris Ventures streamline access to accelerate programmes from Claris's portfolio companies into the clinic 06.03.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. CLARIS’S PORTFOLIO COMPANIES RECEIVE EASY ACCESS TO EVOTEC’S FULL RANGE OF PRE-CLINICAL AND CLINICAL DEVELOPMENT AND MANUFACTURING CAPABILITIES AGREEMENT BUILDS ON SUCCESSFUL COLLABORATION BETWEEN EVOTEC AND CLARIS’S PORTFOLIO...
EQS-News: Evotec SE / Schlagwort(e): Sonstiges Evotec und Claris Ventures kooperieren, um Programme von Claris' Portfoliounternehmen in die Klinik zu beschleunigen 06.03.2024 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. CLARIS‘ PORTFOLIOUNTERNEHMEN ERHALTEN EINFACHEN ZUGANG ZU EVOTECS UMFASSENDEM ANGEBOT AN PRÄKLINISCHEN UND KLINISCHEN ENTWICKLUNGS- UND PRODUKTIONSKAPAZITÄTEN DIE VEREINBARUNG BAUT AUF EINER ERFOLGREICHEN ZUSAMMENARBEIT...
CLARIS'S PORTFOLIO COMPANIES RECEIVE EASY ACCESS TO EVOTEC'S FULL RANGE OF PRE-CLINICAL AND CLINICAL DEVELOPMENT AND MANUFACTURING CAPABILITIES AGREEMENT BUILDS ON SUCCESSFUL COLLABORATION BETWEEN EVOTEC AND CLARIS'S PORTFOLIO COMPANY IAMA HAMBURG, GERMANY / TURIN, ITALY / ACCESSWIRE / March 6, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) and biotech venture capital firm Claris Ventures ("Claris") today announced an acceleration framework to...
EQS-News: Evotec SE / Key word(s): Miscellaneous Just – Evotec Biologics expands development and manufacturing agreement with ABL for broadly neutralising antibodies against HIV 07.02.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. JUST – EVOTEC BIOLOGICS TO PROVIDE DEVELOPMENT AND PHASE I CLINICAL MANUFACTURING OF BROADLY NEUTRALISING ANTIBODY AGAINST HIV AGREEMENT BUILDS ON PREVIOUS NIAID-FUNDED COLLABORATION TO DEVELOP A BROADLY NEUTRALISING...
EQS-News: Evotec SE / Schlagwort(e): Sonstiges Just – Evotec Biologics erweitert Kooperation mit ABL zur Entwicklung und Herstellung breit neutralisierender Antikörper gegen HIV 07.02.2024 / 07:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. JUST – EVOTEC BIOLOGICS WIRD BREIT NEUTRALISIERENDE ANTIKÖRPER GEGEN HIV ENTWICKELN UND FÜR EINE KLINISCHE PHASE-I-STUDIE HERSTELLEN VEREINBARUNG BAUT AUF VORHERIGER VON NIAID FINANZIERTER KOOPERATION ZUR...
JUST - EVOTEC BIOLOGICS TO PROVIDE DEVELOPMENT AND PHASE I CLINICAL MANUFACTURING OF BROADLY NEUTRALISING ANTIBODY AGAINST HIV AGREEMENT BUILDS ON PREVIOUS NIAID-FUNDED COLLABORATION TO DEVELOP A BROADLY NEUTRALISING ANTIBODY AGAINST HIV HAMBURG, GERMANY / ACCESSWIRE / February 7, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that its Seattle-based subsidiary Just - Evotec Biologics, Inc. has expanded its relationship with Advanced...